Table 1.
Characteristics | Number |
---|---|
| |
No. of patients | 20 |
No. of eyes | 25 |
Age (mean years ± SD) | 35.8 ± 17.0 |
Follow-up duration (mean months, range) | 15 (3 – 96) |
Gender n (%) | |
Male | 8/20 (4.0%) |
Female | 12/20 (60.0%) |
Refractive error n (%) | |
Myopic | 24/25 (96.0%) |
Emmetropic | 1/25 (4.0%) |
SE (mean diopters, range) | −5.50 (−12.0 to 0) |
BCVA (mean Snellen equivalent) | |
Initial | 20/33 |
Final | 20/26 |
Presenting symptom, n (%) | |
Vision loss | 15/20 (75.0%) |
Scotoma | 5/20 (25.0%) |
Photopsia | 1/20 (5.0%) |
Treatments n (%) | |
Oral corticosteroid | 18/20 (90.0%) |
Periocular corticosteroid | 2/20 (10.0%) |
Immunosuppressive therapy | 2/20 (10.0%) |
Abbreviations: BCVA: best-corrected visual acuity; SE: spherical equivalent